Dipa Patel
ImClone Systems
11 Papers
97 Citations
Dipa Patel is an academic researcher from ImClone Systems. The author has contributed to research in topics: Cetuximab & Epidermal growth factor receptor. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity
Dan Lu,Haifan Zhang,Henry Koo,James R. Tonra,Paul Balderes,Marie Prewett,Eric Corcoran,Venkata R.M. Mangalampalli,Rajiv Bassi,Deborah Anselma,Dipa Patel,Xiaoqiang Kang,Dale L. Ludwig,Daniel J. Hicklin,Peter Bohlen,Larry Witte,Zhenping Zhu +16 more
TL;DR: A recombinant human IgG-like bispecific antibody, a Di-diabody, produced using the variable regions from two antagonistic antibodies that binds to both EGFR and IGFR and effectively blocked both EGF- and IGF-stimulated receptor activation and tumor cell proliferation.
310
•Journal Article
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.
Dipa Patel,Armin Lahiji,Sheetal Patel,Matthew C. Franklin,Xenia Jimenez,Daniel J. Hicklin,Xiaoqiang Kang +6 more
TL;DR: The data suggest that cetuximab may be a potential candidate for the treatment of tumors that also express EGFRvIII, a truncated form of EGFR that does not bind ligand, is constitutively active, and is reported to be coexpressed with EGFR in some human tumors.
150
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
TL;DR: Results suggest that cetuximab may be useful in the treatment of carcinomas co-expressing EGFR and HER2.
IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab
Dipa Patel,Xuemei Guo,Stanley Ng,Maxine Melchior,Paul Balderes,Douglas Burtrum,Kris Persaud,Xenia Luna,Dale L. Ludwig,Xiaoqiang Kang +9 more
TL;DR: Findings suggest that ADCC may contribute to the antitumor activity of cetuximab, an anti-epidermal growth factor receptor (EGFR) IgG1 antibody, in vitro.
76
•Journal Article
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.
Dipa Patel,Rajiv Bassi,Andrea T. Hooper,Haijun Sun,James Huber,Daniel J. Hicklin,Xiaoqiang Kang +6 more
TL;DR: A combined modality approach that provides passive immunity to melanoma differentiation antigens as well as inhibiting tumor neovascularization may be valuable for the treatment of malignant melanoma.
24